Prolia contains denosumab, a monoclonal antibody that blocks RANKL, a protein responsible for activating osteoclasts (the cells that break down bone). This helps reduce bone loss and increase bone density.
Indications:
-
Treatment of osteoporosis in postmenopausal women at high risk of fractures.
-
Treatment of osteoporosis in men at increased risk of fractures.
-
Bone loss due to hormone-deprivation therapy in breast cancer or prostate cancer patients.
-
Bone loss associated with long-term corticosteroid or immunosuppressive therapy.
Warnings & Precautions:
-
Must be administered under medical supervision.
-
Can cause low blood calcium; adequate calcium and vitamin D intake should be ensured before and during therapy.
-
May cause skin infections (cellulitis).
-
Rarely, may lead to osteonecrosis of the jaw, especially in patients with dental problems.
-
Sudden discontinuation may increase fracture risk; stopping should be managed with a doctor’s plan.
-
Not recommended during pregnancy or breastfeeding.
Reviews
There are no reviews yet.